Literature DB >> 19428741

Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening.

Mohamad Aljofan1, Simon Saubern, Adam G Meyer, Glenn Marsh, Joanne Meers, Bruce A Mungall.   

Abstract

We have recently described the development and validation of a high throughput screening assay suitable for henipavirus antiviral identification. While we are confident this assay is robust and effective, we wished to investigate assay performance in a range of alternative cell lines to determine if assay sensitivity and specificity could be improved. We evaluated ten different cell lines for their susceptibility to Hendra and Nipah virus infection and their sensitivity of detection of the effects of the broad spectrum antiviral, ribavirin and nine novel antivirals identified using our initial screening approach. Cell lines were grouped into three categories with respect to viral replication. Virus replicated best in Vero and BSR cells, followed by Hep-2, HeLa, BHK-21 and M17 cells. The lowest levels of RNA replication and viral protein expression were observed in BAEC, MMEC, A549 and ECV304 cells. Eight cell lines appeared to be similarly effective at discriminating the antiviral effects of ribavirin (<2.7-fold difference). The two cells lines most sensitive to the effect of ribavirin (ECV304 and BAEC) also displayed the lowest levels of viral replication while Vero cells were the least sensitive suggesting excess viral replication may limit drug efficacy and cell lines which limit viral replication may result in enhanced antiviral efficacy. However, there was no consistent trend observed with the other nine antivirals tested. While improvements in antiviral sensitivity in other cell lines may indicate an important role in future HTS assays, the slightly lower sensitivity to antiviral detection in Vero cells has inherent advantages in reducing the number of partially effective lead molecules identified during initial screens. Comparison of a panel of 54 novel antiviral compounds identified during routine screening of an in-house compound library in Vero, BHK-21 and BSR cells suggests no clear advantage of screening in either cell type.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428741      PMCID: PMC2744099          DOI: 10.1016/j.virusres.2009.01.014

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  45 in total

1.  Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83.

Authors:  J Brown; S J Reading; S Jones; C J Fitchett; J Howl; A Martin; C L Longland; F Michelangeli; Y E Dubrova; C A Brown
Journal:  Lab Invest       Date:  2000-01       Impact factor: 5.662

2.  Interactions in vivo between the proteins of infectious bursal disease virus: capsid protein VP3 interacts with the RNA-dependent RNA polymerase, VP1.

Authors:  M G Tacken; P J Rottier; A L Gielkens; B P Peeters
Journal:  J Gen Virol       Date:  2000-01       Impact factor: 3.891

3.  Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.

Authors:  L De Franceschi; G Fattovich; F Turrini; K Ayi; C Brugnara; F Manzato; F Noventa; A M Stanzial; P Solero; R Corrocher
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

4.  Isolation of Hendra virus from pteropid bats: a natural reservoir of Hendra virus.

Authors:  K Halpin; P L Young; H E Field; J S Mackenzie
Journal:  J Gen Virol       Date:  2000-08       Impact factor: 3.891

5.  Person-to-person transmission of Nipah virus in a Bangladeshi community.

Authors:  Emily S Gurley; Joel M Montgomery; M Jahangir Hossain; Michael Bell; Abul Kalam Azad; Mohammed Rafiqul Islam; Mohammed Abdur Rahim Molla; Darin S Carroll; Thomas G Ksiazek; Paul A Rota; Luis Lowe; James A Comer; Pierre Rollin; Markus Czub; Allen Grolla; Heinz Feldmann; Stephen P Luby; Jennifer L Woodward; Robert F Breiman
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

6.  The C, V and W proteins of Nipah virus inhibit minigenome replication.

Authors:  Katrina Sleeman; Bettina Bankamp; Kimberly B Hummel; Michael K Lo; William J Bellini; Paul A Rota
Journal:  J Gen Virol       Date:  2008-05       Impact factor: 3.891

7.  Henipavirus V protein association with Polo-like kinase reveals functional overlap with STAT1 binding and interferon evasion.

Authors:  Louise E Ludlow; Michael K Lo; Jason J Rodriguez; Paul A Rota; Curt M Horvath
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

Review 8.  The emergence of Nipah virus, a highly pathogenic paramyxovirus.

Authors:  Michael K Lo; Paul A Rota
Journal:  J Clin Virol       Date:  2008-10-02       Impact factor: 3.168

9.  Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus.

Authors:  Mohamad Aljofan; Matteo Porotto; Anne Moscona; Bruce A Mungall
Journal:  J Virol Methods       Date:  2008-03-04       Impact factor: 2.014

10.  Inhibition of Henipavirus infection by RNA interference.

Authors:  Bruce A Mungall; Nick C T Schopman; Luke S Lambeth; Tim J Doran
Journal:  Antiviral Res       Date:  2008-08-05       Impact factor: 5.970

View more
  14 in total

1.  Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection.

Authors:  Tatyana Yun; Arnold Park; Terence E Hill; Olivier Pernet; Shannon M Beaty; Terry L Juelich; Jennifer K Smith; Lihong Zhang; Yao E Wang; Frederic Vigant; Junling Gao; Ping Wu; Benhur Lee; Alexander N Freiberg
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

Review 2.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

Review 3.  Emerging paramyxoviruses: molecular mechanisms and antiviral strategies.

Authors:  Hector C Aguilar; Benhur Lee
Journal:  Expert Rev Mol Med       Date:  2011-02-24       Impact factor: 5.600

Review 4.  A treatment for and vaccine against the deadly Hendra and Nipah viruses.

Authors:  Christopher C Broder; Kai Xu; Dimitar B Nikolov; Zhongyu Zhu; Dimiter S Dimitrov; Deborah Middleton; Jackie Pallister; Thomas W Geisbert; Katharine N Bossart; Lin-Fa Wang
Journal:  Antiviral Res       Date:  2013-07-06       Impact factor: 5.970

Review 5.  Henipavirus infection of the central nervous system.

Authors:  Brian E Dawes; Alexander N Freiberg
Journal:  Pathog Dis       Date:  2019-03-01       Impact factor: 3.166

6.  A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment.

Authors:  Barry Rockx; Katharine N Bossart; Friederike Feldmann; Joan B Geisbert; Andrew C Hickey; Douglas Brining; Julie Callison; David Safronetz; Andrea Marzi; Lisa Kercher; Dan Long; Christopher C Broder; Heinz Feldmann; Thomas W Geisbert
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

7.  Off Label Antiviral Therapeutics for Henipaviruses: New Light Through Old Windows.

Authors:  Mohamad Aljofan; Michael K Lo; Paul A Rota; Wojtek P Michalski; Bruce A Mungall
Journal:  J Antivir Antiretrovir       Date:  2010-01-01

8.  Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection.

Authors:  Alexander N Freiberg; Melissa N Worthy; Benhur Lee; Michael R Holbrook
Journal:  J Gen Virol       Date:  2009-11-04       Impact factor: 3.891

9.  Characterization of the Bas-Congo virus glycoprotein and its function in pseudotyped viruses.

Authors:  Imke Steffen; Nathan M Liss; Bradley S Schneider; Joseph N Fair; Charles Y Chiu; Graham Simmons
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

10.  Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro.

Authors:  Mohamad Aljofan; Michael L Sganga; Michael K Lo; Christina L Rootes; Matteo Porotto; Adam G Meyer; Simon Saubern; Anne Moscona; Bruce A Mungall
Journal:  Virol J       Date:  2009-11-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.